中等大分割图像引导调强放疗治疗局限期前列腺癌的II期试验长期结果
这项II期试验评估了60Gy与66Gy两种中等大分割IG-IMRT方案治疗局限期前列腺癌的长期毒性和生化控制。66Gy组因晚期3-4级毒性过高提前终止入组。60Gy组8年晚期≥2级GI和GU毒性分别为4%和12%,66Gy组分别为21%和4%;60Gy组5年和8年FFBF为81%和66%,66Gy组为88%和80%。
要点
- 60Gy中等大分割IG-IMRT的8年晚期≥2级GI毒性4%、GU毒性12%。
- 66Gy组因晚期3-4级毒性过高提前终止入组,8年晚期≥2级GI毒性21%。
- 60Gy组5年和8年FFBF分别为81%和66%,66Gy组为88%和80%。
核心结论
- 60Gy中等大分割IG-IMRT晚期毒性较好,但5年后仍可见晚期泌尿毒性和生化失败。
- 剂量提升至66Gy与显著更差的晚期毒性相关。
研究设计与样本
- II期试验,纳入局限期前列腺癌男性,接受图像引导调强放疗(IG-IMRT),剂量为60Gy或66Gy,分次剂量3Gy。
- 60Gy组中位随访128个月,66Gy组中位随访108个月。
主要发现
- 60Gy组8年累积晚期≥2级GI毒性为4%,GU毒性为12%。
- 66Gy组8年晚期≥2级GI毒性为21%,GU毒性为4%。
- 60Gy组5年和8年FFBF分别为81%和66%。
- 66Gy组5年和8年FFBF分别为88%和80%。
临床怎么用
- 局限期前列腺癌采用60Gy/3Gy中等大分割IG-IMRT时,需关注5年后的晚期泌尿毒性和生化失败。
- 不推荐将剂量提升至66Gy/3Gy,因该方案与显著更差的晚期毒性相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate long-term radiation toxicity and biochemical control of two moderately hypofractionated radiotherapy regimens for prostate cancer. MATERIAL AND METHODS: Eligible men with localized prostate cancer received image-guided intensity modulated radiotherapy (IG-IMRT) to a dose of 60 or 66Gy in 3Gy fractions in a phase II trial. Endpoints included late gastrointestinal (GI) and genitourinary (GU) toxicity and biochemical failure (FFBF). RESULTS: Ninety-six men received 60Gy and 27 received 66Gy. Accrual to the 66Gy cohort terminated early due to excessive Grade 3-4 late toxicity. Median follow-up was 128months (60Gy) and 108months (66Gy). In the 60Gy cohort, cumulative late Grade ⩾2 GI and GU toxicity at 8years was 4% and 12% respectively. In the 66Gy cohort, late Grade ⩾2 GI and GU toxicity was 21% and 4% respectively at 8years. The 5- and 8-year FFBF for 60Gy was 81% and 66%, and for 66Gy was 88% and 80%. CONCLUSIONS: Moderate hypofractionation with IG-IMRT to 60Gy was associated with favorable late toxicity although late urinary toxicity and biochemical failures were observed beyond 5years. Dose escalation to 66Gy was associated with significantly worse late toxicity.
引用
- Lieng H, Pintilie M, Bayley A, et al. Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiother Oncol. 2016. PMID: 27838147. doi:10.1016/j.radonc.2016.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。